Advances in Therapy

, Volume 29, Issue 5, pp 442–455 | Cite as

Microbiological Etiology and Susceptibility of Bacterial Conjunctivitis Isolates from Clinical Trials with Ophthalmic, Twice-Daily Besifloxacin

  • Wolfgang Haas
  • Lynne S. Gearinger
  • Christine K. Hesje
  • Christine M. Sanfilippo
  • Timothy W. Morris
Original Research



Bacterial conjunctivitis is a contagious infection of the surface of the eye usually treated empirically with topical antibiotics. Since the etiologic agent is rarely identified, it is important to monitor which bacteria cause conjunctivitis and determine their antibacterial resistance profiles.


A total of 496 bacterial samples were isolated during a randomized, double-masked, vehicle-controlled, parallel-group study conducted in the United States with besifloxacin ophthalmic suspension 0.6% dosed twice daily. Species were determined by standard biochemical and/or molecular identification methods. Minimum inhibitory concentrations were determined according to Clinical and Laboratory Standards Institute standards.


The most prevalent species was Haemophilus influenzae, followed by Staphylococcus epidermidis, Staphylococcus aureus, the Streptococcus mitis group, and Streptococcus pneumoniae. One species identified in this study, which was not previously noted as a common cause of bacterial conjunctivitis, was Dolosigranulum pigrum. Ampicillin resistance was common among H. influenzae isolates, while macrolide resistance was high among S. pneumoniae, S. epidermidis, and S. aureus. The latter two species also included a number of isolates resistant to methicillin and ciprofloxacin.


Antibiotic resistance among isolates remains a concern and the appearance of an emerging ocular pathogen, D. pigrum, suggests the need for continued observation. The topical ophthalmic fluoroquinolones continue to provide a good balance of low to moderate (i.e., manageable) levels of resistance plus broad-spectrum coverage for empiric treatment of ocular infections.


Antimicrobial efficacy Bacterial conjunctivitis Besifloxacin Fluoroquinolone Ophthalmic suspension 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med. 2008;75:507–512.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Brien TP, Jeng BH, McDonald M, Raizman MB. Acute conjunctivitis: truth and misconceptions. Curr Med Res Opin. 2009;25:1953–1961.PubMedCrossRefGoogle Scholar
  3. 3.
    Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008;86:5–17.PubMedGoogle Scholar
  4. 4.
    Golde KT, Gardiner MF. Bacterial conjunctivitis in children: a current review of pathogens and treatment. Int Ophthalmol Clin. 2011;51:85–92.PubMedCrossRefGoogle Scholar
  5. 5.
    American Academy of Ophthalmology. American Academy of Ophthalmology Cornea/External Disease Panel; Preferred Practice Pattern Guidelines. Conjunctivitis. San Francisco, CA: American Academy of Ophthalmology; 2008.Google Scholar
  6. 6.
    Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369–1379.PubMedGoogle Scholar
  7. 7.
    Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008;145:951–958.PubMedCrossRefGoogle Scholar
  8. 8.
    Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011;152:567–574.PubMedCrossRefGoogle Scholar
  9. 9.
    Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in South Florida. Ophthalmology. 2008;115:51–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. Clin Ophthalmol. 2010;4:215–225.PubMedCrossRefGoogle Scholar
  11. 11.
    Carter NJ, Scott LJ. Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70:83–97.PubMedCrossRefGoogle Scholar
  12. 12.
    Bertino JS, Zhang JZ. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Exp Opin Pharmacother. 2009;10:2545–2554.CrossRefGoogle Scholar
  13. 13.
    Haas W, Pillar CP, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53:3552–3560.PubMedCrossRefGoogle Scholar
  14. 14.
    Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2010;65:1441–1447.PubMedCrossRefGoogle Scholar
  15. 15.
    Sanfilippo CM, Hesje CK, Haas W, Morris TW. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57:363–371.PubMedCrossRefGoogle Scholar
  16. 16.
    McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116:1615–1623.PubMedCrossRefGoogle Scholar
  17. 17.
    Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, doublemasked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31:514–526.PubMedCrossRefGoogle Scholar
  18. 18.
    Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25:1159–1169.PubMedCrossRefGoogle Scholar
  19. 19.
    DeLeon J, Silverstein BE, Allaire C, et al. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. Clin Drug Investig. 2012;32:303–317.PubMedCrossRefGoogle Scholar
  20. 20.
    Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Clin Ther. 2011;33:13–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981;1:523–534.PubMedCrossRefGoogle Scholar
  22. 22.
    Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112:29S–33S.PubMedGoogle Scholar
  23. 23.
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement M100-S21. 31. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2011.Google Scholar
  24. 24.
    Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. 2011;249:111–119.PubMedCrossRefGoogle Scholar
  25. 25.
    Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of Clinical Microbiology. Washington, D.C.: ASM Press; 2007.Google Scholar
  26. 26.
    Leighton C, Piper D, Gunerman-King J. Pneumococcal conjunctivitis at an elementary school—Maine, September 20–December 6, 2002. MMWR Morb Mortal Wkly Rep. 2003;52:64–66.Google Scholar
  27. 27.
    Barker JH, Musher DM, Silberman R, Phan HM, Watson DA. Genetic relatedness among nontypeable pneumococci implicated in sporadic cases of conjunctivitis. J Clin Microbiol. 1999;37:4039–4041.PubMedGoogle Scholar
  28. 28.
    Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003;348:1112–1121.PubMedCrossRefGoogle Scholar
  29. 29.
    Sanfilippo CM, Haas W, Hesje CK, Morris TW. Strain ST448 causes the majority of pneumococcal conjunctivitis cases. Abstract A226. Paper presented at: Annual meeting of The Association for Research in Vision and Ophthalmology; May 6, 2012; Ft. Lauderdale, Florida, USA.Google Scholar
  30. 30.
    Aguirre M, Morrison D, Cookson BD, Gay FW, Collins MD. Phenotypic and phylogenetic characterization of some Gemella-like organisms from human infections: description of Dolosigranulum pigrum gen. nov., sp. nov. J Appl Bacteriol. 1993;75:608–612.PubMedCrossRefGoogle Scholar
  31. 31.
    Laclaire L, Facklam R. Antimicrobial susceptibility and clinical sources of Dolosigranulum pigrum cultures. Antimicrob Agents Chemother. 2000;44:2001–2003.PubMedCrossRefGoogle Scholar
  32. 32.
    Tauber S, Cupp G, Garber R, Bartell J, Vohra F, Stroman D. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Adv Ther. 2011;28:566–574.PubMedCrossRefGoogle Scholar
  33. 33.
    Dong Q, Brulc JM, Iovieno A, et al. Diversity of bacteria at healthy human conjunctiva. Invest Ophthalmol Vis Sci. 2011;52:5408–5413.PubMedCrossRefGoogle Scholar
  34. 34.
    Bertino JS. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol. 2009;3:507–521.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2012

Authors and Affiliations

  • Wolfgang Haas
    • 1
  • Lynne S. Gearinger
    • 1
  • Christine K. Hesje
    • 1
  • Christine M. Sanfilippo
    • 1
  • Timothy W. Morris
    • 1
  1. 1.Bausch & LombRochesterUSA

Personalised recommendations